Kavita Nair, PhD, FAAN, shares how new therapies and ongoing clinical trials are reshaping the future of neurological care and offering new hope to patients.
A new proteomic analysis is shedding a fresh light on the cytokine networks fueling idiopathic pulmonary fibrosis (IPF), ...
A new report affirms that surgical resection is generally sufficient for pediatric patients with low-risk ...
CKD prevalence has more than doubled since 1990, with 788 million adults affected in 2023, highlighting a significant global health challenge. The disease is a major contributor to cardiovascular ...
Genetic predisposition to rheumatoid arthritis increases the risk of interstitial lung disease by 15.5%, as shown by Mendelian randomization analysis. The study used 52 single nucleotide polymorphisms ...
Despite untreated HBV being linked to earlier mortality, higher all-cause and liver-related death, and a 10% to 25% lifetime risk of developing hepatocellular carcinoma (HCC), only 29% of qualifying ...
New data supporting the safety and efficacy of tapinarof cream 1% (Vtama; Organon) for pediatric patients with atopic ...
The FDA approved the combination of pembrolizumab (Keytruda) and enfortumab vedotin-ejfv (Padcev) for neoadjuvant and ...
Michael Hassett, MD, explains the evolving landscape of HER2-positive breast cancer treatment and the role of CDK inhibition ...
Panelists discuss how reinstating LDL-C targets in quality programs could improve outcomes and accountability. Stay ahead of ...
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health ...
The FDA today approved selumetinib (Koselugo; Alexion, AstraZeneca Rare Disease) for the treatment of adults with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback